Paris, April 10, 2020 – French drug firm Sanofi has committed to donating 100 million doses of hydroxychloroquine to 50 countries around the world and has begun to progressively deliver the medicine to authorities that have requested it.
In this global health emergency, Sanofi said in a press release that we are ready to assist as many countries as possible, starting with countries where its medicine is registered for currently approved indications as well as countries where there are no hydroxychloroquine suppliers or countries with underserved populations.
Since the beginning of the COVID-19 crisis, Sanofi has received a growing number of requests from local governments around the world. The company is regularly evaluating its increasing supply capacity and re-assessing how best to help those countries in the most ethical way. Sanofi’s priority is to ensure supply continuity for patients treated under the current approved indications of the medicine, notably including lupus and rheumatoid arthritis, while working hard to supply governments wishing to increase stocks in the hope that it may be an effective treatment of COVID-19.
Sanofi will continue to donate the medicine to governments and hospital institutions if ongoing clinical studies demonstrate its efficacy and safety in COVID-19 patients.
Sanofi has already doubled its incremental production capacity (on top of the usual production for current indications) across its eight hydroxychloroquine manufacturing sites worldwide and is on track to quadruple it by the summer.
At this point, the interpretations of the available preliminary data on hydroxychloroquine in the management of COVID-19 differ widely. In this context, patient safety must always be the guiding principle.
Hydroxychloroquine has several serious known side effects and should be used with caution. Not everyone can take this medicine.
To date, there is insufficient clinical evidence to draw any conclusion over the safety and efficacy of hydroxychloroquine in the management of COVID-19 patients. It is one of several medicines being investigated by the World Health Organization (WHO) in its international clinical trial seeking a treatment solution for COVID-19. Sanofi is supporting ongoing trials by providing the medicine to some participating investigator sites and other independent research centers.
While hydroxychloroquine is generating a lot of hope for patients around the world, it should be remembered that there are no results from ongoing studies, and the results may be positive or negative.
In a statement, the company said, it increased its production capacity by 50% across its eight hydroxychloroquine manufacturing sites worldwide, adding it was on track to quadruple it by the summer.
“Sanofi is calling for coordination among the entire hydroxychloroquine chain worldwide to ensure the continued supply of the medicine if proven to be a well-tolerated and effective treatment in COVID-19 patients”, it said.
Earlier, NYT reported that US President has a personal financial interest in french firm Sanofi and that’s why he is creating pressure on India, the world leader in hydroxychloroquine making pills to export the large number of hydroxychloroquine pills to the US.
However, A Sanofi spokeswoman Ashleigh Koss said the company no longer sells or distributes Plaquenil in the United States, although it does sell it internationally.
займ деньги до зарплатывзять долгосрочный займзайм до 50000 займ под птс новосибирсксправедливый займвзять займ у частного лица